223 related articles for article (PubMed ID: 16091248)
21. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
22. The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.
Lee GA; Schwarz JM; Patzek S; Kim S; Dyachenko A; Wen M; Mulligan K; Schambelan M; Grunfeld C
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):246-8. PubMed ID: 19680131
[TBL] [Abstract][Full Text] [Related]
23. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
Mulligan K; Grunfeld C; Tai VW; Algren H; Pang M; Chernoff DN; Lo JC; Schambelan M
J Acquir Immune Defic Syndr; 2000 Jan; 23(1):35-43. PubMed ID: 10708054
[TBL] [Abstract][Full Text] [Related]
24. Adverse drug reactions to protease inhibitors.
Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
[TBL] [Abstract][Full Text] [Related]
25. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
26. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus.
Carper MJ; Cade WT; Cam M; Zhang S; Shalev A; Yarasheski KE; Ramanadham S
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E558-67. PubMed ID: 18171911
[TBL] [Abstract][Full Text] [Related]
27. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
Cohen CJ
AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
[TBL] [Abstract][Full Text] [Related]
28. Effects of HIV protease inhibitor therapy on lipid metabolism.
Hui DY
Prog Lipid Res; 2003 Mar; 42(2):81-92. PubMed ID: 12547652
[TBL] [Abstract][Full Text] [Related]
29. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
Temple ME; Koranyi KI; Nahata MC
Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
Lagathu C; Bastard JP; Auclair M; Maachi M; Kornprobst M; Capeau J; Caron M
Antivir Ther; 2004 Dec; 9(6):911-20. PubMed ID: 15651750
[TBL] [Abstract][Full Text] [Related]
31. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
Schwenk A
Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
[No Abstract] [Full Text] [Related]
32. Insulin resistance and diabetes in HIV infection.
Das S
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):260-8. PubMed ID: 21824074
[TBL] [Abstract][Full Text] [Related]
33. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
34. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
[TBL] [Abstract][Full Text] [Related]
35. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
[TBL] [Abstract][Full Text] [Related]
36. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
[TBL] [Abstract][Full Text] [Related]
37. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
38. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
39. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
[TBL] [Abstract][Full Text] [Related]
40. Protease therapy and changes to insulin and glucose.
TreatmentUpdate; 1999 Jun; 11(4):5-6. PubMed ID: 11366792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
